Tower Research Capital LLC TRC Increases Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Tower Research Capital LLC TRC increased its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 252.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,615 shares of the company’s stock after acquiring an additional 2,589 shares during the period. Tower Research Capital LLC TRC’s holdings in Zentalis Pharmaceuticals were worth $55,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZNTL. Rafferty Asset Management LLC raised its stake in shares of Zentalis Pharmaceuticals by 79.4% in the fourth quarter. Rafferty Asset Management LLC now owns 360,125 shares of the company’s stock worth $5,456,000 after purchasing an additional 159,439 shares during the last quarter. Decheng Capital LLC acquired a new position in Zentalis Pharmaceuticals in the 4th quarter worth about $31,809,000. TD Asset Management Inc boosted its position in Zentalis Pharmaceuticals by 5.2% during the fourth quarter. TD Asset Management Inc now owns 190,168 shares of the company’s stock worth $2,881,000 after purchasing an additional 9,400 shares in the last quarter. Quest Partners LLC acquired a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $38,000. Finally, E Fund Management Co. Ltd. increased its position in shares of Zentalis Pharmaceuticals by 87.6% in the fourth quarter. E Fund Management Co. Ltd. now owns 19,340 shares of the company’s stock valued at $293,000 after buying an additional 9,033 shares in the last quarter.

Zentalis Pharmaceuticals Stock Up 3.3 %

Shares of Zentalis Pharmaceuticals stock traded up $0.36 on Monday, hitting $11.42. 514,305 shares of the company were exchanged, compared to its average volume of 793,302. The company has a 50-day moving average price of $14.05 and a 200 day moving average price of $13.72. The stock has a market capitalization of $810.36 million, a price-to-earnings ratio of -2.52 and a beta of 1.73. Zentalis Pharmaceuticals, Inc. has a 1-year low of $9.56 and a 1-year high of $31.46.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Tuesday, February 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.09. Research analysts forecast that Zentalis Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ZNTL. HC Wainwright reissued a “buy” rating and issued a $46.00 price target on shares of Zentalis Pharmaceuticals in a research note on Wednesday, February 28th. Wedbush increased their target price on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.57.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $11.44, for a total value of $29,435.12. Following the transaction, the chief financial officer now directly owns 451,449 shares in the company, valued at approximately $5,164,576.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 6.10% of the stock is currently owned by insiders.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.